2,400+ researchers supplied
99+ COAs published
6-panel tested every lot
Processing within 1–3 business days
FREE SHIPFree U.S. shipping on orders over $150Free U.S. shipping on orders over $150
Free U.S. shipping on orders over $150BPC-157 and Thymosin Beta-4 are research peptides investigated for complementary roles in tissue protection, vascular signaling, and cytoskeletal remodeling.
The overlapping yet distinct mechanisms that may support coordinated repair biology, though combination evidence remains early and primarily exploratory.
BPC-157 (Body Protection Compound-157) is a synthetic 15-amino acid peptide based on a naturally occurring fragment of human gastric protein. The peptide is stable in the gastric environment and has systemic effects.
It has been studied for its role in tissue protection, angiogenesis, and cellular repair signaling. Unlike many peptides that act through a single receptor, BPC-157 appears to influence multiple biological pathways involved in vascular integrity, inflammation modulation, and cell migration [1, 2, 3].
Preclinical research shows that BPC-157 interacts with signaling systems relevant to tissue homeostasis during stress and injury, such as [4, 5]:
Thymosin Beta-4 (TB-4) is a 43-amino acid peptide naturally expressed in many tissues, with high concentrations in platelets, immune cells, and sites of tissue injury [6].
It plays a central role in actin regulation, binding to monomeric actin (G-actin) and influencing cytoskeletal remodeling, cell migration, and wound repair processes [7].
In research models, Thymosin Beta-4 supports [8, 9]:
These effects contribute to coordinated tissue regeneration across epithelial, musculoskeletal, and cardiovascular systems.
Unlike growth factors that directly stimulate proliferation, TB-4 is a regulatory peptide, helping cells respond appropriately to injury or stress by organizing structural and signaling pathways.
Although BPC-157 and Thymosin Beta-4 (TB-4) are distinct peptides with different primary functions, their mechanisms of action are highly complementary.
Mechanistically, BPC-157 is associated with cytoprotection and vascular signaling, while Thymosin Beta-4 is more involved in cytoskeletal remodeling and cell migration.
Together, these activities span multiple phases of tissue response to injury or stress.
BPC-157 supports endothelial stability and angiogenic signaling, partly through interactions with nitric oxide pathways and VEGF-related mechanisms [10].
TB-4, in parallel, promotes angiogenesis by facilitating endothelial cell migration and organization via actin dynamics [11].
In combination, these effects may support both vascular signaling and structural assembly during tissue repair.
BPC-157 can be cytoprotective, helping tissues maintain function under inflammatory or ischemic stress [12].
TB-4 contributes to immune regulation by influencing macrophage behavior and reducing excessive inflammatory signaling in injury models [13].
These overlapping but non-redundant roles can potentially coordinate the inflammatory microenvironment.
TB-4’s role in actin sequestration and cytoskeletal flexibility is critical for cell migration, a key step in wound closure and regeneration.
BPC-157, meanwhile, appears to support the biochemical conditions that allow migrating cells to survive, attach, and integrate into repairing tissue.
This creates a conceptual framework in which TB-4 mobilizes cells, while BPC-157 supports the environment they move into.
Currently, direct studies examining BPC-157 and Thymosin Beta-4 together are limited, particularly in human clinical contexts. Most available evidence comes from separate in vitro and in vivo studies that describe overlapping outcomes.
A retrospective observational study evaluated whether intra-articular administration of BPC-157, alone or in combination with Thymosin Beta-4 (TB-4), improved knee pain in 17 patients with different kinds of knee pain [14].
Twelve patients with differing types of knee injuries received 4 mg of BPC-157, while 4 patients the combination of BPC-157 + TB-4 in various doses, including 2 mg BPC-157 + 3 mg TB-4, 2 mg BPC-157 + 3 mg TB-4, 3 mg BPC-157 + 4.5 mg TB-4, and 4 mg BPC-157 + 6 mg TB-4).
11 of 12 patients who received BPC-157 treatment alone reported significant improvement in knee pain. Whereas, 3 out of 4 patients who received the combination of BPC-157 and TB-4 reported significant improvement. The one patient in the combination group who did not experience pain improvement received 2 mg of BPC-157 + 3 mg of TB-4, even though another patient receiving the same dose experienced relief.
50%+ of patients in this study experienced pain relief for 6 months to 1 year. Overall, this was a small retrospective study involving a heterogeneous group of patients with promising results. It’s widely known that pain alone is not an indicator of damage or tissue repair, which might have been better assessed with pre- and post-treatment imaging [15].
Therefore, larger, controlled studies incorporating objective imaging and functional outcomes are needed to clarify efficacy, durability, and comparative benefits.
In rats, intramuscular administration of BPC-157 results in a half life of about 30 minutes in the blood [5]. In human tissues, it is estimated that levels may drop from peak amounts by 50% within 24 hours post-administration. As a result, daily administration may be essential to maintain its effects.
TB-4 has a longer half life as it binds to plasma proteins and actin in tissues, resulting in effects that may last days or weeks. The daily administration of TB-4 may allow the peptide to build up.
Anecdotally, the 1:1 combo of BPC-157 and TB-4 is within the typical dosage ranges of both peptides. Daily doses of 300–500 mcg of each peptide are well-tolerated, with fatigue being a potential side effect. This combination delivers synergistic immune and tissue-healing benefits.
1 Seiwerth, S., Brcic, L., Vuletic, L. B., Kolenc, D., Aralica, G., Misic, M., et al. (2014) BPC 157 and blood vessels. Curr. Pharm. Des., Curr Pharm Des 20, 1121–1125
2 Vasireddi, N., Hahamyan, H., Salata, M. J., Karns, M., Calcei, J. G., Voos, J. E., et al. (2025) Emerging use of BPC-157 in orthopaedic sports medicine: A systematic review. HSS J., SAGE Publications 21, 15563316251355551
3 Chang, C.-H., Tsai, W.-C., Lin, M.-S., Hsu, Y.-H. and Pang, J.-H. S. (2011) The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J. Appl. Physiol., American Physiological Society 110, 774–780
4 Hsieh, M.-J., Lee, C.-H., Chueh, H.-Y., Chang, G.-J., Huang, H.-Y., Lin, Y., et al. (2020) Modulatory effects of BPC 157 on vasomotor tone and the activation of Src-Caveolin-1-endothelial nitric oxide synthase pathway. Sci. Rep., Springer Science and Business Media LLC 10, 17078
5 McGuire, F. P., Martinez, R., Lenz, A., Skinner, L. and Cushman, D. M. (2025) Regeneration or risk? A narrative review of BPC-157 for musculoskeletal healing. Curr. Rev. Musculoskelet. Med., Springer Science and Business Media LLC 18, 611–619
6 Goldstein, A. L., Hannappel, E., Sosne, G. and Kleinman, H. K. (2012) Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin. Biol. Ther. 12, 37–51
7 Xue, B., Leyrat, C., Grimes, J. M. and Robinson, R. C. (2014) Structural basis of thymosin-β4/profilin exchange leading to actin filament polymerization. Proc. Natl. Acad. Sci. U. S. A. 111, E4596–605
8 Philp, D., Huff, T., Gho, Y. S., Hannappel, E. and Kleinman, H. K. (2003) The actin binding site on thymosin beta4 promotes angiogenesis. FASEB J., Wiley 17, 2103–2105
9 Ye, L., Zhang, P., Duval, S., Su, L., Xiong, Q. and Zhang, J. (2013) Thymosin β4 increases the potency of transplanted mesenchymal stem cells for myocardial repair. Circulation, Ovid Technologies (Wolters Kluwer Health) 128, S32–41
10 Hsieh, M.-J., Liu, H.-T., Wang, C.-N., Huang, H.-Y., Lin, Y., Ko, Y.-S., et al. (2017) Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J. Mol. Med., J Mol Med (Berl) 95, 323–333
11 Selmi, A., Malinowski, M., Brutkowski, W., Bednarek, R. and Cierniewski, C. S. (2012) Thymosin β4 promotes the migration of endothelial cells without intracellular Ca2+ elevation. Exp. Cell Res., Elsevier BV 318, 1659–1666
12 Sikiric, P., Skrtic, A., Gojkovic, S., Krezic, I., Zizek, H., Lovric, E., et al. (2022) Cytoprotective gastric pentadecapeptide BPC 157 resolves major vessel occlusion disturbances, ischemia-reperfusion injury following Pringle maneuver, and Budd-Chiari syndrome. World J. Gastroenterol., Baishideng Publishing Group Inc. 28, 23–46
13 Zhu, Z., Liao, Y., Mou, Q., Liu, H., Shen, Y., Zhu, L., et al. (2025) Thymosin β4 regulates tissue inflammatory response in mouse nonalcoholic fatty liver disease by promoting macrophage M2-type polarization. J. Inflamm. Res. 18, 5791–5809
14 Lee, E. and Padgett, B. (2021) Intra-articular injection of BPC 157 for multiple types of knee pain. Altern. Ther. Health Med., Altern Ther Health Med 27, 8–13
15 Raja, S. N., Carr, D. B., Cohen, M., Finnerup, N. B., Flor, H., Gibson, S., et al. (2020) The revised International Association for the Study of Pain definition of pain: concepts, challenges, and compromises: concepts, challenges, and compromises. Pain, Ovid Technologies (Wolters Kluwer Health) 161, 1976–1982
Research Use Only. All findings described above are derived from preclinical studies (animal models and in vitro experiments). BPC157 + Thymosin Beta-4 is not approved by the FDA for any diagnostic or therapeutic use in humans. Genesis Peptides makes no claims regarding human clinical efficacy. This product is sold exclusively for laboratory research.
Every lot undergoes six independent assays before release. Results are published in the lot-specific Certificate of Analysis.
BPC-157, also called Bpc-157, is a synthetic pentadecapeptide derived from gastric proteins. It has shown notable reparative and anti-inflammatory properties across diverse preclinical models. A separate study describes it as a gastric pentadecapeptide and investigated its inhibitory potential alongside two newly designed hybrid analogs, CIARA-1 and CIARA-2.
One review names TB-500 as a thymosin beta-4 fragment and lists it among unapproved peptides marketed direct to patients. A separate scoping review states that thymosin beta-4, also called TB-500, is one of six emerging peptides it summarizes for musculoskeletal recovery and enhancement in animal and human models.
In animal studies, BPC 157 was reported to support new blood vessel formation (angiogenesis), collagen production (collagen synthesis), fibroblast activity, and modulation of nitric oxide pathways. These effects were described as contributing to enhanced healing of muscle, tendon, ligament, bone, and gastrointestinal tissue in those animal studies. In a laboratory study using human arterial tissue, BPC 157 induced concentration-dependent vasorelaxation, predominantly mediated via an endothelium-dependent nitric oxide pathway.
According to the review, thymosin beta 4 (TB4) has not received full US Food and Drug Administration approval. The review reports that studies show TB4 significantly promotes corneal wound healing after injury, and that this led to a clinical trial of RGN-259, with full FDA approval still pending. The review also states that most of these regenerative peptides, which include TB-4, remain unapproved by the FDA, and that clinical evidence in humans is limited.
In preclinical animal studies, BPC 157 was reported to support angiogenesis, collagen synthesis, fibroblast activity, and modulation of nitric oxide pathways. These effects were described as contributing to enhanced healing of muscle, tendon, ligament, bone, and gastrointestinal tissue in those studies. In animal studies, BPC 157 was proposed to protect skeletal muscle against ischemia-reperfusion injury by attenuating oxidative stress, modulating apoptosis, reducing inflammation, and supporting angiogenic activity.
In a randomized, placebo-controlled, double-blind trial of 96 STEMI patients, the overall difference in infarcted area between the rhTB4 group and the placebo group was not significant. In a subgroup of that trial, infarcted areas were significantly reduced at 90-day follow-up in patients whose first rhTB4 dose was given within 8 h after PCI (n = 43) compared with placebo.
A review states that independent blinded replication, dose-response and therapeutic-window studies, pharmacokinetic/pharmacodynamic characterization, rigorous toxicology, and ultimately controlled human studies would be required before clinical translation of BPC 157 could be considered. The same review describes BPC-157 as an unapproved peptide sold on the unregulated (illicit) market, and states that it lacks an established human safety profile.
In structural modeling, the tandem form (tTB4) was found to be able to simultaneously bind and sequester two G-actin molecules, which gave it a mechanistic advantage over standard TB4 in enhancing actin polymerization. In a murine alkali-induced corneal injury model, tTB4 promoted corneal wound healing and reduced scarring with greater efficacy than TB4. Because tTB4 can be produced by bacterial fermentation, its synthesis is described as simplified and more cost-effective than that of TB4.
The facts do not describe BPC 157's legal status in any specific country. A review states that BPC-157 has no approved formulation, no validated dosing regimen, and no completed Phase II clinical trial. The same review describes BPC-157 as an unapproved peptide sold on the unregulated (illicit) market, and says it lacks an established human safety profile.
In a mouse model of Pseudomonas aeruginosa keratitis, adjunctive thymosin beta 4 (Tβ4) combined with ciprofloxacin markedly improved visual acuity and contrast sensitivity compared with PBS, Tβ4 alone, and ciprofloxacin alone. In the infected mice, the combination of Tβ4 and ciprofloxacin also restored corneal nerve density and architecture to levels comparable to those of uninfected control mice. In this animal study, the treatments were given as topical drops three times daily, starting 24 hours after infection.
A review of human clinical studies of the reviewed peptides, including BPC-157, found that such studies were limited to a handful of investigations, most lacking robust controls or rigorous study designs. The same review stated that the claimed benefits of emerging peptide supplements, including BPC-157, for musculoskeletal recovery and performance remain unsubstantiated by current human trials.
In rat studies, TB-500 treatment was associated with increased type I collagen organization and altered type III collagen distribution on Sirius red birefringence analysis, particularly in the TB-500 group. Histopathological evaluation in rats showed significantly lower total Bonar scores in the TB-500 group (p = 0.016), and significantly lower total Movin scores in the TB-500 and BPC + TB groups relative to controls, indicating improved tendon architecture. In rats, biomechanical testing found higher maximum load to failure values in the BPC-157 and TB-500 groups than in controls, with the difference reaching statistical significance in the TB-500 group (p < 0.05).
FOR RESEARCH USE ONLY — Products are sold exclusively for in vitro and preclinical laboratory research. Not for human consumption or administration. Not intended for diagnostic or therapeutic use. These statements have not been evaluated by the FDA.